顺铂子宫动脉介入栓塞联合紫杉醇静脉化疗在局部晚期宫颈癌治疗中的应用

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (45 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical combined application of uterine artery embolization with cisplatin and paclitaxel chemotherapy in the treatment of locally advanced cervical cancer patients.Methods Retrospectively analized 152 cases locally advanced cervical cancer patients in our hospital from January 2006 to June 2013.54 cases were combined treated by uterine artery embolization with cisplatin and intravenous chemotherapy（artery+vein group），while 52 cases were treated with uterine artery embolization with cisplatin（artery group），and 46 cases received intravenous chemotherapy（vein group）.Patients were treated with paclitaxel combined with cisplatin，paclitaxel 135 mg/m2and cisplatin 70 mg/m2，and received radical uterus resection surgery and lymph node dissection or radiation therapy after 1-2 courses.The clinical efficacy and adverse reaction，completion rate of the surgery，blood loss，the operation time，resection margin negative rate and postoperative 3 years survival rate of patients were observed.Results The tumor size of artery+ vein group and artery group were significantly reduced.5 cases of intravenous group had disease progression.The total effective rate of the artery+vein group and artery group were higher than that of intravenous group with statistical difference（P＜0.05）.There were 47cases，44 cases and 30 cases underwent uterine resection surgery and lymph node dissection in artery+vein group，artery group and intravenous group respectively with statistical difference（P＜0.05）.Operation time of artery+vein group and artery group were　（180.1±40.4），（180.2±30.3）min，shorter than　（210.4±30.2）min of intravenous group with statistical difference（P＜0.05）.Blood loss of artery+vein group and artery group were（265.6±50.2），（280.2±55.1）ml，less than （350.6±45.7）ml of intravenous group with statistical difference（P＜0.05）.The resection margin negative rate of the two groups was significantly higher than that of intravenous group with statistical difference（P＜0.05）.All patients were alive and without recurrence for 3 years after operation.Conclusion Cisplatin uterine artery embolization combined with paclitaxel intravenous chemotherapy can retain the advantages of uterine artery embolization chemotherapy，and reduce the adverse reactions.It is a better way to the neoadjuvant chemotherapy for locally advanced cervical cancer.

Key words： Cervical cancer Neoadjuvant chemotherapy Adverse drug reaction Route of administration

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Shu-zhen
	YANG Mei
	ZENG Chun-jie
	WANG Guo-dong

Cite this article:

ZHANG Shu-zhen,YANG Mei,ZENG Chun-jie, et al. Clinical combined application of uterine artery embolization with cisplatin and paclitaxel chemotherapy in locally advanced cervical cancer patients[J]. 中国当代医药, 2016, 23(22): 116-119.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I22/116

［1］	谢幸，苟文丽.妇产科学［M］.8版，北京：人民卫生出版社，2013：304.
［2］	Jernal A，Bray F，Center MM，et al.Global cancer statistics［J］. CA Cancer J clin，2011，61（2）：69-90.
［3］	Ghaemmaghami F，Saleh-Gargari S，Sahebdel B，et al.Risk factors and clinical aspects of recurrent invasive cervical carcinoma［J］.J Obstet Gynaecol India，2012，62（6）：674-678.
［4］	Slama J，Dundr P，Dusek L，et al.High false negative rate of frozen section examination of sentinel lymph nodes in patients with cervical cancer［J］.Gynecol Oncol，2013，129（2）：384-388.
［5］	邢艳，吴玉梅.局部晚期宫颈癌新辅助化疗研究进展［J］.肿瘤学杂志，2014，20（12）：967-971.
［6］	Frei E.Clinical cancer research：an embattled specics［J］. Cancer，1982，50（10）：1979-1992.
［7］	Koh WJ，Greer BE，Abu-Rustum NR，et al.Cervical cancer［J］. J Natl Compr Canc Netw，2013，11（3）：320-343.
［8］	Minig L，Patrono MG，Romero N，et al.Different strategies of treatment for uterine cervical carcinoma stageⅠB2-ⅡB［J］. World J Clin Oncol，2014，5（2）：86-92.
［9］	任锦霞，王小虎，赵林.紫杉醇+顺铂同步放化疗治疗局部中晚期宫颈癌的临床观察［J］.兰州大学学报，医学版，2009，35（2）：54-57.
［10］	候岩峰，程晓伟，承莉，等.术前新辅助化疗治疗局部晚期宫颈癌临床疗效的观察［J］.肿瘤基础与临床，2011，24 （3）：213-215.
［11］	张蓉，李斌，白萍，等.紫杉醇联合铂类在局部晚期宫颈癌新辅助化疗中的应用［J］.中华肿瘤杂志，2011，33（8）：616-620.
［12］	Adachi S，Ogasawara T，Tsubamoto H，et al.Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cancer［J］.Int J Clin Pharmacol Res，2001，21（3）：105-110.
［13］	Chhetri　G，Ghosh　A，Chinta　R，et　al.Cloning，soluble expression，andpurificationoftheRNApolymeraseⅡsubunit RPB5 from Saccharomyces cerevisiae［J］.Bioengineered，2015，6（1）：62-66.
［14］	Shan　L，Tang　R，Liu　S，etal.Prokaryotic　expression，purification and preparation of polyclonal antibody for wheat grain peroxidase WP1 gene［J］.Sheng Wu Gong Cheng Xue Bao，2011，27（1）：26-30.
［15］	Peciak K，Tommasi R，Choi JW，et al.Expression of soluble and active interferon consensus in SUMO fusion expression system in E.coli［J］.Protein Expr Purif，2014，7（99）：18-26.